New Antifolates: Pharmacology and Clinical Applications
- PMID: 10387971
New Antifolates: Pharmacology and Clinical Applications
Abstract
Many new antifolate compounds with unique clinical properties are currently in clinical development. Some of these agents have been rationally designed to circumvent known mechanisms of resistance to methotrexate, the most useful and extensively studied antifolate in clinical practice. Resistance to methotrexate can result from decreased active transport into cells, decreased polyglutamation resulting in enhanced drug efflux from cells, mutations in dihydrofolate reductase which reduce drug binding affinity, and increased expression of dihydrofolate reductase due to gene amplification or increased translational efficiency. As a consequence, the newer antifolates may differ from methotrexate because of increased lipid solubility, improved cellular uptake or increased ability to undergo polyglutamation. Several of these newer agents also uniquely target specific folate-dependent enzymes such as thymidylate synthase or glycinamide ribonucleotide transformylase. Antifolates currently in clinical development include trimetrexate, edatrexate, piritrexim, ZD1694, lometrexol, AG337, LY231514 and 1843U89. This report summarizes the basic pharmacology and potential clinical applications of these promising new agents.
Similar articles
-
Novel antifolate drugs.Curr Oncol Rep. 2003 Mar;5(2):114-25. doi: 10.1007/s11912-003-0098-3. Curr Oncol Rep. 2003. PMID: 12583828 Review.
-
Molecular basis of antifolate resistance.Cancer Metastasis Rev. 2007 Mar;26(1):153-81. doi: 10.1007/s10555-007-9049-z. Cancer Metastasis Rev. 2007. PMID: 17333344 Review.
-
Antifolates in clinical development.Semin Oncol. 1997 Oct;24(5 Suppl 18):S18-40-S18-51. Semin Oncol. 1997. PMID: 9420020 Review.
-
New antifolates in clinical development.Oncology (Williston Park). 1995 Jul;9(7):649-56, 659 DISC 660, 662, 665. Oncology (Williston Park). 1995. PMID: 8924375 Review.
-
Antifolate resistance and its circumvention by new analogues.Hum Cell. 2001 Sep;14(3):185-202. Hum Cell. 2001. PMID: 11774738 Review.
Cited by
-
The effect of inhibiting glycinamide ribonucleotide formyl transferase on the development of neural tube in mice.Nutr Metab (Lond). 2016 Aug 23;13(1):56. doi: 10.1186/s12986-016-0114-x. eCollection 2016. Nutr Metab (Lond). 2016. PMID: 27555878 Free PMC article.
-
Pharmacokinetics, bioavailability, and plasma protein binding study of glytrexate, a novel multitarget antifolate.Front Pharmacol. 2022 Oct 4;13:1001308. doi: 10.3389/fphar.2022.1001308. eCollection 2022. Front Pharmacol. 2022. PMID: 36267288 Free PMC article.
-
Sequential optimization of methotrexate encapsulation in micellar nano-networks of polyethyleneimine ionomer containing redox-sensitive cross-links.Int J Nanomedicine. 2014 Jun 6;9:2833-48. doi: 10.2147/IJN.S61614. eCollection 2014. Int J Nanomedicine. 2014. PMID: 24944513 Free PMC article.
-
Cancer chemotherapy: targeting folic acid synthesis.Cancer Manag Res. 2010 Nov 19;2:293-301. doi: 10.2147/CMR.S10043. Cancer Manag Res. 2010. PMID: 21301589 Free PMC article.
-
Novel antifolate drugs.Curr Oncol Rep. 2003 Mar;5(2):114-25. doi: 10.1007/s11912-003-0098-3. Curr Oncol Rep. 2003. PMID: 12583828 Review.
LinkOut - more resources
Other Literature Sources
Research Materials